dc.contributor.author |
Sarici, Ahmet |
|
dc.contributor.author |
Kaya, Emin |
|
dc.contributor.author |
Erkurt, Mehmet Ali |
|
dc.contributor.author |
Berber, Ilhami |
|
dc.contributor.author |
Tanrıverdi, Lokman Hekim |
|
dc.contributor.author |
Bahçecioğlu, Ömer Faruk |
|
dc.contributor.author |
Gök, Selim |
|
dc.contributor.author |
Kuku, Irfan |
|
dc.date.accessioned |
2022-12-06T08:45:33Z |
|
dc.date.available |
2022-12-06T08:45:33Z |
|
dc.date.issued |
2021 |
|
dc.identifier.citation |
SARİCİ A, KAYA E, ERKURT M, BERBER I, TANRİVERDİ L, BAHCECİOGLU O, GOK S, KUKU I (2021). Comparison of the renal response of bortezomib-based induction and conventional regimen in multiple myeloma patients with renal failure. Annals of Medical Research, 28(10), 1824 - 1829. 10.5455/annalsmedres.2021.01.098 |
en_US |
dc.identifier.uri |
https://search.trdizin.gov.tr/yayin/detay/482619/comparison-of-the-renal-response-of-bortezomib-based-induction-and-conventional-regimen-in-multiple-myeloma-patients-with-renal-failure |
|
dc.identifier.uri |
http://hdl.handle.net/11616/85629 |
|
dc.description.abstract |
Aim: Vincristine-doxorubicin-dexamethasone (VAD) was the commonly used first-line treatment for multiple myeloma (MM) patients with renal failure before bortezomib entered clinical practice. In this trial, we aimed to compare the effect of VAD and bortezomibcyclophosphamide-dexamethasone (VCD) chemotherapy regimens on improving kidney function in MM patients with renal failure. Materials and Methods: The records of MM patients in our center between January 2010 and February 2020 were retrospectively analyzed. Patients who received VAD or VCD as a first treatment chemotherapy protocol and whose initially estimated glomerular filtration rate (eGFR) was 50 mL/min/1.73 m2and below were included in the study. Patients were divided into two groups according to the chemotherapy regimens they received. Results: Sixty one MM patients (VAD: 26, VCD: 35) were included in the study. No significant difference was found between the VAD and VCD groups when the baseline, 1st and 2nd month eGFRs were compared (p>0.05). Overall renal response rate (at least minor response) in the VCD group at the end of the 1st month were higher than in the VAD group (p=0.002). Also, renal response rate in the VCD group at the end of the 2nd month were higher than in the VAD group (p=0.033). Conclusion: In MM patients with renal insufficiency, overall renal response rates have increased with the use of VCD instead of VAD as a standard induction regimen. |
en_US |
dc.language.iso |
eng |
en_US |
dc.rights |
info:eu-repo/semantics/openAccess |
en_US |
dc.title |
Comparison of the renal response of bortezomib-based induction and conventional regimen in multiple myeloma patients with renal failure |
en_US |
dc.type |
article |
en_US |
dc.relation.ispartof |
Annals of Medical Research |
en_US |
dc.department |
İnönü Üniversitesi |
en_US |